Longevity clinic at Bumrungrad Hospital adopts proteomics test that predicts patients’ current and future risk of multiple chronic diseases.
Japanese technology giant NEC has revealed that its FonesVisuas blood test has been adopted by the VitalLife longevity clinic at Bumrungrad International Hospital in Bangkok, Thailand. The test evaluates thousands of proteins from a single blood sample to visualize an individual’s current and future health status and risks for diseases, including dementia, heart attack, lung cancer and chronic kidney disease.
Consistently recognized as one of the world’s best hospitals, Bumrungrad is known for its early adoption of advanced medical technologies. The hospital’s VitalLife center is focused on personalized healthcare and longevity, integrating cutting-edge technology and biomarkers to detect potential health risks and apply personalized interventions promptly.
VitalLife’s adoption of the FonesVisuas test aims to enhance the clinic’s ability to predict patients’ risk of disease by analyzing changes in proteins. Powered by the SomaScan Platform from proteomics company SomaLogic, the FonesVisuas test provides extensive insights into protein biology and interactions by measuring more than 7,000 proteins simultaneously from a single sample.
The VitalLife deployment is the first deployment of the FonesVisuas test outside Japan, and NEC now plans to expand its provision internationally, particularly in the Asia-Pacific region.
